Shares of Seattle Genetics, Inc. (NASDAQ:SGEN) are tumbling nearly 10% in Monday’s trading session, after the drug maker announced topline data from its ECHELON-1 Phase …
This morning, Immunomedics, Inc. (NASDAQ:IMMU) and Seattle Genetics, Inc.
Cantor analyst Mara Goldstein sheds light on Seattle Genetics, Inc. (NASDAQ:SGEN) after the bad news broke of a FDA partial hold placed on clinical …
Seattle Genetics, Inc. (NASDAQ:SGEN) reported financial results for the fourth quarter and year ended December 31, 2015.
Seattle Genetics, Inc. (NASDAQ:SGEN) reported financial results for the second quarter and six months ended June 30, 2015.
Seattle Genetics, Inc. (NASDAQ:SGEN) announced the initiation of a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in systemic lupus erythematosus (SLE, or lupus).
Seattle Genetics, Inc. (NASDAQ:SGEN) is a biotechnology company involved in developing antibody-based therapies for the treatment of cancer.
Seattle Genetics, Inc. (NASDAQ:SGEN) today highlighted the company’s broad presence at the upcoming 106th Annual Meeting of the American Association for Cancer Research(AACR) …